Contradicted and initially stronger effects in highly cited clinical research

被引:986
作者
Ioannidis, JPA [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece
[2] Tufts Univ New England Med Ctr, Dept Med, Inst Clin Res & Hlth Policy Studies, Boston, MA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 294卷 / 02期
关键词
D O I
10.1001/jama.294.2.218
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Controversy and uncertainty ensue when the results of clinical research on the effectiveness of interventions are subsequently contradicted. Controversies are most prominent when high-impact research is involved. Objectives To understand how frequently highly cited studies are contradicted or find effects that are stronger than in other similar studies and to discern whether specific characteristics are associated with such refutation over time. Design All original clinical research studies published in 3 major general clinical journals or high-impact-factor specialty journals in 1990-2003 and cited more than 1000 times in the literature were examined. Main Outcome Measure The results of highly cited articles were compared against subsequent studies of comparable or larger sample size and similar or better controlled designs. The same analysis was also performed comparatively for matched studies that were not so highly cited. Results Of 49 highly cited original clinical research studies, 45 claimed that the intervention was effective. Of these, 7 (16%) were contradicted by subsequent studies, 7 others (16%) had found effects that were stronger than those of subsequent studies, 20 (44%) were replicated, and 11 (24%) remained largely unchallenged. Five of 6 highly-cited nonrandomized studies had been contradicted or had found stronger effects vs 9 of 39 randomized controlled trials (P=.008). Among randomized trials, studies with contradicted or stronger effects were smaller (P=.009) than replicated or unchallenged studies although there was no statistically significant difference in their early or overall citation impact. Matched control studies did not have a significantly different share of refuted results than highly cited studies, but they included more studies with "negative" results. Conclusions Contradiction and initially stronger effects are not unusual in highly cited research of clinical interventions and their outcomes. The extent to which high citations may provoke contradictions and vice versa needs more study. Controversies are most common with highly cited nonrandomized studies, but even the most highly cited randomized trials may be challenged and refuted over time, especially small ones.
引用
收藏
页码:218 / 228
页数:11
相关论文
共 164 条
  • [41] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Fisher, B
    Costantino, JP
    Wickerham, DL
    Redmond, CK
    Kavanah, M
    Cronin, WM
    Vogel, V
    Robidoux, A
    Dimitrov, N
    Atkins, J
    Daly, M
    Wieand, S
    Tan-Chiu, E
    Ford, L
    Wolmark, N
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) : 1371 - 1388
  • [42] Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction:: a systematic overview of data from individual patients
    Flather, MD
    Yusuf, S
    Kober, L
    Pfeffer, M
    Hall, A
    Murray, G
    Torp-Pedersen, C
    Ball, S
    Pogue, J
    Moyé, L
    Braunwald, E
    [J]. LANCET, 2000, 355 (9215) : 1575 - 1581
  • [43] Surrogate end points in clinical trials: Are we being misled?
    Fleming, TR
    DeMets, DL
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) : 605 - 613
  • [44] A DOUBLE-BLIND TRIAL OF ORAL PROGESTERONE, ALPRAZOLAM, AND PLACEBO IN TREATMENT OF SEVERE PREMENSTRUAL-SYNDROME
    FREEMAN, EW
    RICKELS, K
    SONDHEIMER, SJ
    POLANSKY, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01): : 51 - 57
  • [45] Gallo C, 1998, LANCET, V352, P17
  • [46] GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450
  • [47] Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer:: Who benefits and by how much?
    Gill, S
    Loprinzi, CL
    Sargent, DJ
    Thomé, SD
    Alberts, SR
    Haller, DG
    Benedetti, J
    Francini, G
    Shepherd, LE
    Seitz, JF
    Labianca, R
    Chen, W
    Cha, SS
    Heldebrant, MP
    Goldberg, RM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) : 1797 - 1806
  • [48] Giorgi A, 1999, J Sci Med Sport, V2, P341, DOI 10.1016/S1440-2440(99)80007-3
  • [49] Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
    Grady, D
    Herrington, D
    Bittner, V
    Blumenthal, R
    Davidson, M
    Hlatky, M
    Hsia, J
    Hulley, S
    Herd, A
    Khan, S
    Newby, LK
    Waters, D
    Vittinghoff, E
    Wenger, N
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (01): : 49 - 57
  • [50] Effects of early childhood supplementation with and without stimulation on later development in stunted Jamaican children
    GranthamMcGregor, SM
    Walker, SP
    Chang, SM
    Powell, CA
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1997, 66 (02) : 247 - 253